Bio-Techne Corporation recently reported past second-quarter and six-month results to December 31, 2025, with sales essentially flat year-on-year at about US$295.88 million for the quarter and US$582.

Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript February 4, 2026 Bio-Techne Corporation beats earnings ...

Feb 4 (Reuters) - Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development. The ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

Bio-Techne (NASDAQ: TECH) just disclosed its Q2 earnings on Wednesday, February 4, 2026 at 06:30 AM. Here's a brief overview ...

Shares of Bio-Techne Corp. TECH slid 2.41% to $63.98 Thursday, on what proved to be an all-around mixed trading session for ...

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

The company's 10-Ks for fiscal year 2025 identify certain factors that could cause the company's actual results to differ ...

Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...